Avalon GloboCare Announces Breakthrough in Identifying Human Angiogenic Exosomes/Extracellular Vesicles (EV) Derived from Endothelial Cells
Angiogenic exosomes containing angiogenic factors developed to promote new blood vessel formation and tissue regeneration upon release from exosomes.
Results from Avalon’s co-development program with Weill Cornell Medicine led by Yen-Michael Hsu, M.D., Ph.D., Director of cGMP Cellular Therapy Facility and Laboratory for Advanced Cellular Engineering.
Accepted as podium presentation at the International Society of Extracellular Vesicles (ISEV) 2019 Annual Meeting, Kyoto, Japan.
FREEHOLD, N.J., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO) (NASDAQ listed Avalon GloboCare AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that its ongoing co-development program with Weill Cornell Medicine, led by Yen-Michael Hsu, M.D., Ph.D., Director of cGMP Cellular Therapy Facility and Laboratory for Advanced Cellular Engineering, has identified novel human angiogenic exosomes/extracellular cellular vesicles (EV) derived from endothelial cells. These angiogenic exosomes contain angiogenic factors developed to promote new blood vessel formation and tissue regeneration upon release from exosomes. A podium presentation titled “Novel Angiogenic Extracellular Vesicles Induced by StemReginin1” will be presented by Dr. Hsu at the upcoming Annual ISEV Meeting in Kyoto, Japan.
“Identification and isolation of tissue-specific exosomes is considered by many as the “Holy Grail” in this area,” stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare. “This discovery is essential for future development of endothelial cell-derived angiogenic exosomes in treating ischemic vascular diseases, as well as contribution to tissue and organ regeneration,” added Dr. Jin.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to advancing cell-based technologies and therapeutics, with a focus on developing and empowering innovative and transformative cell-based technologies and their clinical applications. In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth, development, as well as competitiveness in both the domestic and global healthcare markets. Through its subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon is establishing a leading role in the fields of exosome-based diagnostics, cellular immunotherapy (including CAR-T/CAR-NK), and regenerative medicine.
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
Crescendo Communications, LLC
Tel: (212) 671-1020